Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma

Shin, Dong‐Yeop; Byun, Byung Hyun; Kim, Kyeong Min; Kang, Joo Hyun; Lim, Ilhan; Lee, Seung-Sook; Choi, Chang Woon; Kang, Hye Jin; Lim, Sang Moo

doi:10.1007/s00280-016-3140-5

Cited by 8 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no study has been conducted in case of RIT. We demonstrated that effect of lanatoside C as a radiosensitizer at 131 I-trastuzumab RIT in HER2 positive cells ( We have performed the clinical trial of RIT for NHL patients using 131 I-rituximab for 16 years [21][22][23][24][25] . RIT demonstrated excellent outcomes, but there are some refractory patients who revealed resistance to RIT.…”

Section: Discussionmentioning

confidence: 99%

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Vinod

Kim

Choi

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor progression in NCI-N87 xenograft model. The combination treatment (131I-trastuzumab and lanatoside C) showed highest cytotoxicity when compared to non-treated control or trastuzumab alone or 131I alone or 131I-trastuzumab alone in vitro. Biodistribution studies using 131I-trastuzumab or combination of 131I-trastuzumab and lanatoside C showed tumor uptake in BALB/c nude mice bearing HER2 positive NCI-N87 tumor xenograft model. The higher tumor uptake was observed in 131I-trastuzumab (19.40±0.04% ID/g) than in the combination of 131I-trastuzumab and lanatoside C (14.02±0.02% ID/g) at 24 hours post-injection. Most importantly, an antitumor effect was observed in mice that received the combination of 131I-trastuzumab and lanatoside C (p=0.009) when compared to control. In addition, mice received lanatoside C alone (p=0.085) or 131I-trastuzumab alone (p=0.160) did not significantly inhibit tumor progression compared with control. Taken together, our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Vinod

Kim

Choi

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…We have performed the clinical trial of RIT for NHL patients using 131 I-rituximab for 17 years 22 – 26 . RIT demonstrated excellent outcomes, but there are some refractory patients who revealed resistance to RIT.…”

Section: Discussionmentioning

confidence: 99%

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Vinod

Kim

Choi

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor progression in NCI-N87 xenograft model. The combination treatment (131I-trastuzumab and lanatoside C) showed highest cytotoxicity when compared to non-treated control or trastuzumab alone or 131I alone or 131I-trastuzumab alone in vitro. Biodistribution studies using 131I-trastuzumab or combination of 131I-trastuzumab and lanatoside C showed tumor uptake in BALB/c nude mice bearing HER2 positive NCI-N87 tumor xenograft model. The higher tumor uptake was observed in 131I-trastuzumab (19.40 ± 0.04% ID/g) than in the combination of 131I-trastuzumab and lanatoside C (14.02 ± 0.02% ID/g) at 24 h post-injection. Most importantly, an antitumor effect was observed in mice that received the combination of 131I-trastuzumab and lanatoside C (p = 0.009) when compared to control. In addition, mice received lanatoside C alone (p = 0.085) or 131I-trastuzumab alone (p = 0.160) did not significantly inhibit tumor progression compared with control. Taken together, our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor.

show abstract

“…We have performed a clinical trial of RIT for NHL patients using 131 I-rituximab for 16 years [8][9][10][11][12]. RIT demonstrated excellent results, but some refractory patients showed resistance to RIT.…”

Section: Discussionmentioning

confidence: 99%

“…Among these radiopharmaceuticals, 131 Irituximab plays a role in treating patients with aggressive CD20-expressing B-cell NHL [4][5][6][7]. Our institute has used RIT for NHL patients using 131 I-rituximab [8][9][10][11][12]. RIT using 131 I-rituximab showed remarkable treatment results, but some patients experienced recurrence after RIT, which reveals 3 resistance to the treatment.…”

Section: Introductionmentioning

confidence: 99%

Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: Dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab

Lee

Lim

Woo

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the radiation dosimetry of 225 Ac-DOTA-rituximab using Monte Carlo simulation of 64 Cu-DOTA-rituximab.Methods: CD20 expression was evaluated in lymphoma cell lines (Jurkat and Raji). DOTA-rituximab was conjugated and then chelated by 64 Cu. Tumor xenograft models were established in BALB/c-nu mice. Animal PET/CT imaging was obtained after tail vein injection with and without a pre-dose of 2 mg of cold rituximab. Specific binding of tumors was evaluated by an organ distribution assay and autoradiography. CD20 expression in tumor tissues was evaluated by immunohistochemistry. The residence time was calculated using 64 Cu-DOTA-rituximab PET/CT acquisition data using OLINDA/EXM software. 225 Ac-DOTA-rituximab dosimetry analysis was performed using Monte Carlo simulation.Results: CD20 protein was highly expressed in Raji cells. Specific binding of Raji cells was 90 times that of Jurkat cells (p<0.0001). Immunoreactivity was more than 75%. PET/CT imaging with 64 Cu-DOTA-rituximab was specifically observed in tumors. The radioactivity of the tumor was much higher than that of other organs, and tumor uptake was related to CD20 expression. The predicted human dose for the administration of 64 Cu-DOTA-rituximab was measured as the effective dose (3.20E-02 mSv/MBq). In the tumor region, equivalent doses of 225 Ac-DOTA-rituximab (14 Sv RBE5 /MBq) were much higher (74-fold) than those of 64 Cu-DOTA-rituximab (0.19 Sv RBE5 /MBq) ( p<0.01 ).Conclusion: Tumor dosimetry of 225 Ac-DOTA-rituximab can be estimated via the Monte Carlo simulation of 64 Cu-DOTA-rituximab. 225 Ac-DOTA-rituximab can be used as targeted alpha therapy for patients with refractory lymphoma.

show abstract

Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma

Abstract: (131)I-rituximab showed promising efficacy as consolidation treatment for patients with DLBCL. A future randomized phase III study to confirm our results is warranted.

Cited by 8 publications

References 27 publications

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: Dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab

Contact Info

Product

Resources

About